The first in SCN8A a rare pediatric epileptic encephalopathy and the second in focal-onset seizures in adults from which we anticipate delivering top-line data in 2023. Shifting gears now to the psychiatry portfolio of assets in license from Takeda Pharmaceuticals. We have initiated Phase 2 studies with all three lead programs, including Luvadaxistat in cognitive impairment associated with schizophrenia, NBI-845 for inadequate response in major depressive disorder and NBI-846 in anhedonia in major depressive disorder. Top-line data for 845 and 846 are anticipated in 2023, staying within psychiatry and the lead muscarinic agonist in our collaboration in Sosei Heptares, NBI-568.